Products for Research Use Only
RegisterLogin

TCRS-417

CAT: 0804-HY-153916-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-153916-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
TCRS-417 (T417) is a small-molecular inhibitor for PBX1. TCRS-417 can directly block PBX1-binding to DNA (IC50 = 6.58 μM), and affects PBX1 transcription. TCRS-417 is able to hammer out the stemness traits of Carboplatin -resistant (CR) cells to revert to a differentiated status through tacking PBX1 signaling cascade. TCRS-417 significantly suppresses self-renewal and proliferation of cancer cells expressing high levels of PBX1. TCRS-417 can decrease the mRNA levels of FOXM1, NEK2, and E2F2 in cancer cell lines. TCRS-417 is selectively toxic against chr1q-amp myeloma and solid tumor cells[1][2][3][4].
CAS Number
2032123-28-5
Product Name Alternative
T417
UNSPSC
12352005
Target
DNA/RNA Synthesis; HOXA; NEKs
Type
Reference compound
Related Pathways
Cell Cycle/DNA Damage
Applications
COVID-19-immunoregulation
Field of Research
Cancer; Inflammation/Immunology; Neurological Disease
Assay Protocol
https://www.medchemexpress.com/tcrs-417.html
Concentration
10mM
Purity
99.13
Solubility
DMSO : 100 mg/mL (ultrasonic; warming; heat to 60°C)
Smiles
O=C(C1=CC(F)=CC=C1)NC2=CC=C(C3=C2C=CC=C3)OCC(NC4=CC=C(C(O)=C4)O)=O
Molecular Formula
C25H19FN2O5
Molecular Weight
446.43
References & Citations
[1]Small molecule compounds targeting pbx1 transcriptional complex.WO2016172437.|[2]Yao-An Shen, et al., Abstract 1966: A novel small-molecule compound targeting PBX1-DNA interaction impedes cancer cell survival and carboplatin resistance. Cancer Res 1 July 2018; 78 (13_Supplement) : 1966.|[3]Trasanidis, N., et al., (2022) . Systems medicine dissection of chr1q-amp reveals a novel PBX1-FOXM1 axis for targeted therapy in multiple myeloma. Blood, 139 (13), 1939–1953.|[4]Shen, Y. A., et al., (2021) . Development of small molecule inhibitors targeting PBX1 transcription signaling as a novel cancer therapeutic strategy. iScience, 24 (11), 103297.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported

Related Products

CatalogName
HY-W953699CRBN ligand-417
HY-P704067Vitronectin, Human (417a.a)
HY-P990515-01Anti-TCR Antibody (NKTT320)
HY-P990159Anti-Mouse TCRβ Antibody (HB218)
HY-P990303-01Anti-Mouse 2C TCR Antibody (1B2)
HY-P990160Anti-Rat TCR alpha/beta Antibody (R73)
HY-P990142Anti-Mouse Vβ4 TCR Antibody (KT4)
HY-P990113Anti-Rat TCR gamma/delta Antibody (V65)
HY-P99146-01Anti-Mouse TCR gamma/delta Antibody (UC7-13D5)
HY-P990141Anti-Mouse Vβ8 TCR Antibody (F23.1)

Alternative Products

CatalogName
GTR19219387-01TCRS-417
GTR19224285-01SLUPP-417
M16583-01MS-417
110067Hsp-417
B7331-10L-838,417
GTR19276742-01CRBN ligand-417
ANTY021038Elk-1 (Ab-417)
MBS857350-01Elk1 (Ab-417) Antibody
MBS1283921-01Recombinant Sulfolobus islandicus rod-shaped virus 1 Uncharacterized protein 417 (417)
MBS1232171Recombinant Giardia intestinalis Major surface-labeled trophozoite antigen 417 (TSA 417), partial

Popular Products